These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23400950)

  • 21. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
    Peggs KS; Quezada SA; Chambers CA; Korman AJ; Allison JP
    J Exp Med; 2009 Aug; 206(8):1717-25. PubMed ID: 19581407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes.
    Stumpf M; Zhou X; Bluestone JA
    J Immunol; 2013 Feb; 190(3):961-9. PubMed ID: 23293354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
    Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
    Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.
    Yu P; Steel JC; Zhang M; Morris JC; Waldmann TA
    Clin Cancer Res; 2010 Dec; 16(24):6019-28. PubMed ID: 20924130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
    Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
    Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory T cells control epitope spreading in autoimmune arthritis independent of cytotoxic T-lymphocyte antigen-4.
    Yang M; Klocke K; Hernandez CM; Xu B; Gjertsson I; Wing K; Holmdahl R
    Immunology; 2018 Dec; 155(4):446-457. PubMed ID: 29992549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
    Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CTLA-4 (CD152) blockade does not cause a pro-inflammatory cytokine profile in regulatory T cells.
    Kolar P; Hoff H; Maschmeyer P; Burmester GR; Brunner-Weinzierl MC
    Clin Exp Rheumatol; 2011; 29(2):254-60. PubMed ID: 21418778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exacerbation of Autoimmune Thyroiditis by CTLA-4 Blockade: A Role for IFNγ-Induced Indoleamine 2, 3-Dioxygenase.
    Sharma R; Di Dalmazi G; Caturegli P
    Thyroid; 2016 Aug; 26(8):1117-24. PubMed ID: 27296629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility.
    Pentcheva-Hoang T; Simpson TR; Montalvo-Ortiz W; Allison JP
    Cancer Immunol Res; 2014 Oct; 2(10):970-80. PubMed ID: 25038199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immature dendritic cells convert anergic nonregulatory T cells into Foxp3- IL-10+ regulatory T cells by engaging CD28 and CTLA-4.
    Pletinckx K; Vaeth M; Schneider T; Beyersdorf N; Hünig T; Berberich-Siebelt F; Lutz MB
    Eur J Immunol; 2015 Feb; 45(2):480-91. PubMed ID: 25382658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsumura H
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18.
    Ma Z; Li W; Yoshiya S; Xu Y; Hata M; El-Darawish Y; Markova T; Yamanishi K; Yamanishi H; Tahara H; Tanaka Y; Okamura H
    Clin Cancer Res; 2016 Jun; 22(12):2969-80. PubMed ID: 26755531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation.
    Li SY; Liu Y; Xu CF; Shen S; Sun R; Du XJ; Xia JX; Zhu YH; Wang J
    J Control Release; 2016 Jun; 231():17-28. PubMed ID: 26829099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4.
    Wing JB; Ise W; Kurosaki T; Sakaguchi S
    Immunity; 2014 Dec; 41(6):1013-25. PubMed ID: 25526312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
    Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
    J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 type 1 diabetes region in nonobese diabetic mice.
    Araki M; Chung D; Liu S; Rainbow DB; Chamberlain G; Garner V; Hunter KM; Vijayakrishnan L; Peterson LB; Oukka M; Sharpe AH; Sobel R; Kuchroo VK; Wicker LS
    J Immunol; 2009 Oct; 183(8):5146-57. PubMed ID: 19783679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced suppression of polyclonal CD8
    Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
    J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
    Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
    Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.